Earnings release
Page 1
image_0.jpg Editas Medicine Announces First Quarter 2025 Results and Business Updates Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Strong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., May 12, 2025 – Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing companyfocused on developing transformative medicines for serious diseases, today reported financial results for the firstquarter 2025 and provided business updates. “We achieved notable progress in the first quarter, advancing our mission and strategy to become a leader in in vivogene editing. This momentum was fueled by recent scientific breakthroughs that bolster our confidence in the near-term potential of CRISPR-based in vivo gene editing therapies,” said Gilmore O’Neill, M.B., M.M.Sc., Presidentand Chief Executive Officer of Editas Medicine. “I’m proud of the strides made by the Editas team in driving ourin vivo gene editing programs, which we believe could unlock significant new therapeutic possibilities. I lookforward to our continued progress towards the clinic.” Dr. O’Neill continued, “I am also thrilled to have welcomed Amy Parison to the executive leadership team as ourCFO. Amy joined Editas in 2022 as our head of Finance, working closely with the CFO, and her track record offinancial decision-making, accounting acumen, and team leadership abilities made her the natural choice for therole.” Recent Achievements and Outlook Upcoming Data Presentations• Editas will present preclinical data to support its development of transformative in vivo gene editingmedicines at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting on May 13-17. Presentations include:◦ In Vivo Delivery of HBG1/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-HumanPrimate with Lipid Nanoparticles.◦ In vivo CRISPR Editing of Genetic Regulatory Regions Results in Functional Upregulation ofTarget Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice.◦ Design and Development of Improved LNP Targeting Ligands for in vivo Hematopoietic Stem CellEditing.◦ Design of Chemically Modified AsCas12a Guide RNAs for Increased Potency of LNP-DeliveredGene Editing Cargos.◦ In vivo Gene Editing and Disease-Associated Biomarker Reduction for Multiple Liver Targets inNon-human Primate Using AsCas12a Nuclease Delivered by LNP.• The Company will also present preclinical data and participate in panel presentations at TIDES USA 2025:Oligonucleotide & Peptide Therapeutics on May 19-22.
Page 2
Hematopoietic Stem Cells• Editas will share in vivo preclinical data from humanized mouse and non-human primate (NHP) studiesdemonstrating the use of targeted lipid nanoparticles (tLNPs) to deliver HBG1/2 promoter editing cargo tohematopoietic stem and progenitor cells (HSPCs) and/or hematopoietic stem cells (HSCs) in bone marrowat ASGCT on May 14. Liver Cells• The Company will share preclinical proof of concept for an undisclosed liver target using in vivo CRISPRediting to upregulate target protein expression and reduce a disease-associated biomarker in a relevantmouse disease model at ASGCT on May 13 and the following week at the TIDES annual meeting.• Additional proof of concept results from the first in vivo mouse and NHP studies demonstrate high levels oftarget gene editing in the liver and corresponding biomarker response following intravenous administrationof AsCas12a messenger RNA (mRNA) and chemically modified guide RNAs (gRNAs) delivered usingLNPs from the Company’s collaborative partner Genevant. Platform Enhancements and Other Cells/Tissues• Editas will share preclinical data demonstrating in vivo gene editing capabilities towards developingtransformative in vivo medicines, including guide modification and targeting moiety optimizations toincrease potency and improve gene editing outcomes in vivo at ASGCT.• Additionally, the Company remains on track to establish and disclose one additional target cell type/tissuebeyond HSCs and liver by year-end. Other Corporate Highlights Leadership• Amy Parison Appointed Chief Financial OfficerMs. Parison has more than 18 years of financial, accounting, and business development experience in lifesciences. During her time at Editas, she has served in multiple roles of increasing responsibilities includingSenior Vice President, Finance, and Vice President and Corporate Controller. In partnership with theexecutive leadership team, she has worked on the Company’s equity financings, licensing transactions androyalty monetization transaction. Prior to Editas, Ms. Parison served as Corporate Controller of RubiusTherapeutics where she led the accounting team following the Company’s IPO, building critical businessand financial processes. Prior to Rubius, she was at Vertex Pharmaceuticals, where she held several roles ofincreasing responsibility within the accounting and finance teams and supported forecasting, budgeting, andbusiness development. She started her career with PricewaterhouseCoopers, LLP. Intellectual Property• The U.S. Court of Appeals for the Federal Circuit vacated the Patent Trial and Appeal Board’s (PTAB’s)previous decision and remanded it back to the PTAB for further review in the U.S. patent interferenceinvolving specific patents for CRISPR/Cas9 editing in human cells between the University of California,the University of Vienna, and Emmanuelle Charpentier and the Broad Institute (Broad).• We remain confident in our IP position and the strength of the Broad patents. First Quarter 2025 Financial ResultsCash, cash equivalents, and marketable securities as of March 31, 2025 were $221.0 million compared to $269.9million as of December 31, 2024. The Company expects the existing cash, cash equivalents, and marketablesecurities and the retained portions of the payments payable under its license
Page 3
agreement with Vertex Pharmaceuticals, will enable the Company to fund its operating expenses and capitalexpenditure requirements into the second quarter of 2027. First Quarter 2025 • For the three months ended March 31, 2025, net loss attributable to common stockholders was $76.1 million, or$0.92 per share, compared to net loss of $62.0 million, or $0.76 per share, for the same period in 2024. • Collaboration and other research and development revenues increased to $4.7 million for the three monthsended March 31, 2025, compared to $1.1 million for the same period in 2024. The increase is primarilyattributable to the recognition of the remaining deferred revenue upon the closing out of a collaborationagreement with a strategic partner. • Research and development expenses decreased by $22.2 million to $26.6 million for the three months endedMarch 31, 2025, compared to $48.8 million for the same period in 2024. The decrease is primarily related toclinical and manufacturing costs related to discontinuation of the clinical development of the Company’s reni-cel program initiated in December 2024, partially offset by costs attributable to in vivo research and discovery. • General and administrative expenses decreased by $6.0 million to $13.4 million for the three months endedMarch 31, 2025, compared to $19.3 million for the same period in 2024. The decrease is primarily related tostock-based compensation expenses related to expense in connection with the achievement of certainperformance-based vesting of restricted stock units recognized in the first quarter of 2024 for which there wasno equivalent expense in the first quarter of 2025. • Restructuring and impairment charges were $40.9 million for the three months ended March 31, 2025,compared to no such charges for the same period in 2024. The restructuring and impairment charges wererelated to the discontinuation of the clinical development of the Company’s reni-cel program initiated inDecember 2024, the related workforce reduction, associated impairment charges for laboratory andmanufacturing equipment related to the reni-cel program and the acceleration in expense due to changes inuseful life estimates for leasehold improvements, software and a right of use asset associated with theCompany’s reni-cel program. Upcoming EventsEditas Medicine plans to participate in the following scientific and medical conferences:• American Society of Gene and Cell Therapy (ASGCT) 28th Annual MeetingMay 13-17, 2025New Orleans, LA • TIDES USA 2025: Oligonucleotide & Peptide TherapeuticsMay 19-22, 2025San Diego, CA Editas Medicine plans to participate in the following investor event:• Bank of America Healthcare Conference 2025May 13, 2025Las Vegas, NV No Conference CallThe Company is no longer hosting quarterly earnings conference calls. About Editas MedicineAs a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of theCRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivomedicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop,manufacture, and commercialize durable, precision in vivo gene
Page 4
editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’sCas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For thelatest information and scientific presentations, please visit www.editasmedicine.com. Forward-Looking StatementsThis press release contains forward-looking statements and information within the meaning of The PrivateSecurities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similarexpressions are intended to identify forward-looking statements, although not all forward-looking statementscontain these identifying words. Forward-looking statements in this press release include statements regarding theinitiation, timing, progress and results of the Company’s preclinical studies and its research and developmentprograms, including the Company’s expectation to declare two in vivo development candidates in mid-2025 andestablish and disclose one additional in vivo target cell type/tissue beyond HSCs and the liver by the end of 2025;the timing for the Company’s receipt and presentation of data from its preclinical studies; the potential of, andexpectations for, the Company’s in vivo product candidates; the timing or likelihood of regulatory filings andapprovals; and the Company’s expectations regarding cash runway into the second quarter of 2027. The Companymay not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, andyou should not place undue reliance on these forward-looking statements. Actual results or events could differmaterially from the plans, intentions and expectations disclosed in these forward-looking statements as a result ofvarious important factors, including: uncertainties inherent in the initiation and completion of preclinical studies;availability and timing of results from preclinical studies; expectations for regulatory approvals to conduct trials;and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses andcapital expenditure requirements. These and other risks are described in greater detail under the caption “RiskFactors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securitiesand Exchange Commission, as updated by the Company’s subsequent filings with the Securities and ExchangeCommission, and in other filings that the Company may make with the Securities and Exchange Commission in thefuture. Any forward-looking statements contained in this press release represent the Company’s views only as ofthe date hereof and should not be relied upon as representing its views as of any subsequent date. Except asrequired by law, the Company explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in thispress release.
Page 5
EDITAS MEDICINE, INC. Consolidated Statement of Operations (amounts in thousands, except share and per share data) (Unaudited) Three Months EndedMarch 31, 2025 2024 Collaboration and other research and development revenues$ 4,658 1,135 Operating expenses: Research and development 26,593 48,787 General and administrative 13,375 19,339 Restructuring and impairment charges 40,853 — Total operating expenses 80,821 68,126 Operating loss (76,163) (66,991) Other income, net: Other (expense) income, net (425) 6 Interest related to sale of future revenues (2,216) — Interest income, net 2,716 5,035 Total other income, net 75 5,041 Net loss $ (76,088)$ (61,950) Net loss per share, basic and diluted $ (0.92)$ (0.76) Weighted-average common shares outstanding, basic anddiluted 83,055,066 81,938,839
Page 6
EDITAS MEDICINE, INC. Selected Consolidated Balance Sheet Items (amounts in thousands) (Unaudited) March 31, December 31, 2025 2024 Cash, cash equivalents, and marketable securities $ 220,964 $ 269,913 Working capital 151,729 212,090 Total assets 263,652 341,589 Deferred revenue, net of current portion 54,204 54,204 Total stockholders' equity 62,420 134,274 ### Media and Investor Contact: ir@editasmed.com